Skip to main content
. 2023 Oct 14;24(20):15179. doi: 10.3390/ijms242015179

Figure 4.

Figure 4

5-Aza synergizes with MGMT silencing to influence TMZ sensitivity in MGMT-UM GSCs. (A) Schematic diagram of TUSC3-activation-centered pharmacological therapeutic strategy through combination of DNMT1 inhibition, MGMT inhibition and TMZ. (B) Immunoblotting of MGMT protein in MGMT-UM GSCs (01 and 02) to examine Lomeguatrib efficiency of MGMT inhibition. β-actin was used as loading control. (C) mRNA expression of TUSC3 was measured by qPCR in MGMT-UM GSCs with indicated single or combination treatment for 72 h. (D) TMZ IC-50 alteration during indicated treatment (4 treatment groups) in MGMT-UM GSCs. Lo, Lomeguatrib. Data are presented as mean ± SD. n = 3; *, p < 0.05.